Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) shares were up 10.6% on Thursday . The company traded as high as $7.84 and last traded at $7.84. Approximately 1,845,719 shares were traded during mid-day trading, an increase of 757% from the average daily volume of 215,450 shares. The stock had previously closed at $7.09.
A number of equities analysts recently commented on AGLE shares. BidaskClub upgraded shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, September 17th. Zacks Investment Research cut Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Aeglea Bio Therapeutics in a report on Wednesday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Aeglea Bio Therapeutics in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $12.31.
The company has a market cap of $349.66 million, a price-to-earnings ratio of -3.33 and a beta of 1.85. The firm’s 50 day simple moving average is $7.07 and its 200-day simple moving average is $7.19.
Hedge funds have recently bought and sold shares of the company. Bank of Montreal Can increased its holdings in shares of Aeglea Bio Therapeutics by 219.1% in the 2nd quarter. Bank of Montreal Can now owns 5,399 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 3,707 shares during the period. BNP Paribas Arbitrage SA grew its position in Aeglea Bio Therapeutics by 150.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 8,073 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 4,849 shares during the last quarter. Citigroup Inc. grew its position in Aeglea Bio Therapeutics by 22.9% during the 1st quarter. Citigroup Inc. now owns 9,355 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,745 shares during the last quarter. Alliancebernstein L.P. acquired a new position in Aeglea Bio Therapeutics in the first quarter valued at $47,000. Finally, Jane Street Group LLC purchased a new stake in shares of Aeglea Bio Therapeutics in the second quarter valued at about $115,000. 85.10% of the stock is owned by institutional investors and hedge funds.
About Aeglea Bio Therapeutics (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Further Reading: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.